Evaluation of the pharmacokinetics and metabolism of a novel histone deacetylase inhibitor, KBH-A40, in rats

Xenobiotica

Volumn 41, Issue 2, 2011, Pages 155-163

  Oh, S J ^a,b   Lee, K ^b   Ryu, J ^b   Yu, H E ^b   Han, G ^c   Park, S K ^b   Kang, J S ^b   Kim, H M ^b   Kim, Y C ^a  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Glucuronidation; HDAC inhibitor; Hydrolysis; KBH A40; KBH A40 carboxylate; Pharmacokinetics

Indexed keywords

3 (2 OXO 1 PHENETHYL 1,2,5,6 TETRAHYDROPYRIDIN 3 YL)PROPANOIC ACID; CYTOCHROME P450; DRUG METABOLITE; HISTONE DEACETYLASE INHIBITOR; KBH A 40; N HYDROXY 3 (2 OXO 1 PHENETHYL 1,2,5,6 TETRAHYDROPYRIDIN 3 YL)PROPANAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STABILITY; DRUG TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; NONHUMAN; QUALITATIVE ANALYSIS; RAT; SPRAGUE DAWLEY RAT; STEADY STATE; TANDEM MASS SPECTROMETRY;

ANIMALS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; GLUCURONIDES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

RATTUS;

EID: 78651366134     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.531790     Document Type: Article

References (35)

1. Artursson P, Borchardt RT. (1997). Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res 14:1655-1658.
2. Artursson P, Palm K, Luthman K. (2001). Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43. (Pubitemid 33653412)
3. Batty N, Malouf GG, Issa JP. (2009). Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280:192-200.
4. Charman WN, Rogge MC, Boddy AW, Barr WH, Berger BM. (1993). Absorption of danazol after administration to diferent sites of the gastrointestinal tract and the relationship to single-and double-peak phenomena in the plasma profles. J Clin Pharmacol 33:1207-1213.
5. Delie F, Rubas W. (1997). A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ter Drug Carrier Syst 14:221-286.
6. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly J F, Ricker JL, Richon VM, Frankel SR. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39. (Pubitemid 46053039)
7. Duvic M, Vu J. (2007). Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111-1120
8. FDA labeling information [online]. 2006.
9. Fogh J, Fogh JM, Orfeo T. (1977). One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59:221-226.
10. Gan L-SL, Takker DR. (1997). Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Deliv Rev 23:77-98.
11. Granero GE, Amidon GL. (2008). Possibility of enterohepatic recycling of ketoprofen in dogs. Int J Pharm 349:166-171.
12. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. (2004). Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59:177-189.
13. Kim HM, Lee K, Park BW, Ryu DK, Kim K, Lee CW, Park SK, Han JW, Lee HY, Lee HY, Han G. (2006). Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett 16:4068-4070.
14. Kim HM, Oh SJ, Park SK, Han G, Kim K, Lee KS, Kang JS, Nam M, Lee K. (2008). In vitro metabolism of KBH-A40, a novel delta-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum. Xenobiotica 38:281-293.
15. Kim HM, Ryu DK, Choi Y Park BW, Lee K, Han SB, Lee CW, Kang MR, Kang JS, Boovanahalli SK, Park SK, Han JW, Chun TG, Lee HY, Nam KY, Choi EH, Han G. (2007). Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors. J Med Chem 50:2737-2741.
16. Lau GS, Critchley JA. (1994). Te estimation of paracetamol and its major metabolites in both plasma and urine by a single high-performance liquid chromatography assay. J Pharm Biomed Anal 12:1563-1572.
17. Lee K, Takker DR. (1999). Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 88:680-687.
18. Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY, Vastag KJ, Nishime JA. (1996). Species diferences in the pharmacokinetics and metabolism of indinavir, a potent human immunodefciency virus protease inhibitor. Drug Metab Dispos 24:1111-1120. (Pubitemid 26346225)
19. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814.
20. Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. (1995). Celiprolol double-peak occurrence and gastric motility: nonlinear mixed efects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 23:267-286.
21. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605.
22. Mottet D, Castronovo V. (2008). Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25:183-189.
23. Mummaneni V, Amidon GL, Dressman JB. (1995). Gastric pH infuences the appearance of double peaks in the plasma concentration-time profles of cimetidine after oral administration in dogs. Pharm Res 12:780-786.
24. Ng SP, Wong KY, Zhang L, Zuo Z, Lin G. (2004). Evaluation of the frst-pass glucuronidation of selected favones in gut by Caco-2 monolayer model. J Pharm Pharm Sci 8:1-9.
25. Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Teoretical considerations of a "well-stirred" model and a "parallel tube" model. Infuence of hepatic blood fow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653.
26. Plusquellec Y Campistron G, Staveris S, Barre J, Jung L, Tillement JP, Houin G. (1987). A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 15:225-239.
27. Press B, Di Grandi D. (2008). Permeability for intestinal absorption: Caco-2 assay and related issues. Curr Drug Metab 9:893-900.
28. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y Lin JH, Pearson PG, Baillie TA. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505-512.
29. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790.
30. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. (2002). Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 76:588-594.
31. Sun H, Chow EC, Liu S, Du Y, Pang KS. (2008). Te Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol 4:395-411.
32. Van Breemen RB, Li Y (2005). Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 1:175-185.
33. Wang Y Roy A, Sun L, Lau CE. (1999). A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 27:855-859.
34. Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. (2005). Te talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728-735.
35. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M. (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455-463.